Abstract
Many studies have been conducted with the aim to stimulate a therapeutic immune response against tumors. In most cases, efforts have been directed toward the induction of tumor-specific cytotoxic T lymphocytes (CTL), because this T lymphocyte subpopulation is considered to play a major role in the destruction of tumor cells (1). In particular, vaccination protocols have been designed to increase the immunogenicity of intact cancer cells by using adjuvants or engineering tumor cells with cytokine or costimulatory molecule genes. A second line of research has employed immunization with tumor-associated antigens (TAA). These antigens are expressed from derepressed or mutated genes in tumor cells, and are recognized by CTL in the form of peptides associated with MHC class I molecules. Genes encoding TAA have been inserted into recombinant viral vectors, which are then used to infect the host’s cells and induce expression of the transgene. Moreover, immunization with purified TAA peptides or with antigen-presenting cells, such as dendritic cells, pulsed with TAA peptides have been proposed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roth, C., Rochlitz, C., and Kourilsky, P. (1994) Immune response against tumors. Adv. Immunol. 57, 281–351.
Donnelly, J. J., Ulmer, J. B., Shiver, J. W., and Liu, M. A. (1997) DNA vaccines. Annu. Rev. Immunol. 15, 617–648.
Boon, T. and Van der Bruggen, P. (1996) Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725–729.
Jaffee, E. M. and Pardoll, D. M. (1996) Murine tumor antigens: is it worth the search? Curr. Opin. Immunol. 8, 622–627.
Restifo, N. P. (1996) The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8, 658–663.
Van den Eynde, B., Lethé, B., Van Pel, A., De Plaen, E., and Boon, T. (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373–1384.
Ramarathinam, L., Sarma, S., Maric, M., Zhao, M., Yang, G., Chen, L., and Liu, Y. (1995) Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 155, 5323–5329.
Rosato, A., Zambon, A., Milan, G., Ciminale, V., D’Agostino, D. M., Macino, B., Zanovello, P., and Collavo, D. (1997) CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum. Gene Ther. 8, 1451–1458.
Whalen, R. G. (1997) The DNA vaccine web. http://www.genweb.com/dnavax/dnavax.html.
Hudson, L. and Hay, F. C. (1989) Mixed-lymphocyte reaction (MLR) and cell-mediated cytolysis (CMC), in Practical Immunology (3rd ed.) Blackwell Science, Oxford, UK, pp. 160–162.
Bachmann, M. F. (1997) Evaluation of lymphocytic choriomeningitis virus-specific cytotoxic T cell responses, in Immunology Methods Manual (Lefkovits, I., ed.), Academic Press, pp. 1919–1933.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Rosato, A., Milan, G., Zambon, A., Zanovello, P., Collavo, D. (2000). CTL Analysis for Tumor Vaccines. In: Lowrie, D.B., Whalen, R.G. (eds) DNA Vaccines. Methods in Molecular Medicine™, vol 29. Humana Press. https://doi.org/10.1385/1-59259-688-6:123
Download citation
DOI: https://doi.org/10.1385/1-59259-688-6:123
Publisher Name: Humana Press
Print ISBN: 978-0-89603-580-5
Online ISBN: 978-1-59259-688-1
eBook Packages: Springer Protocols